QualityStocks would like to highlight
GrowBLOX Sciences, Inc. (
OTCQB: GBLX), a biopharmaceutical research and development company, focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm, to bring relief to patients in communities across the country.
In the company’s news:
Through the commercialization of its proprietary cannabis cultivation technology, GrowBLOX Sciences, Inc. (OTCQB: GBLX) is building a formidable presence in the burgeoning medicinal cannabis industry. In order to capitalize on this position, the company plans to utilize a specialized three phase retail distribution solution that will allow for comprehensive coverage of the country’s legalized medicinal cannabis markets.
Phase one of GrowBLOX’s projected retail channel solutions is The Apothecary. This unique retail environment combines a simple, clean and clinical design with cutting-edge biometrics and patient verification to ensure a pleasant and safe customer experience. When visiting The Apothecary, patients will have access to highly trained and certified patient-care professionals, who will help determine medical needs and identify therapeutic solutions. Since doctors have limited training in the benefits of cannabinoid therapy products, these professionals are essential to the company’s patient education efforts. For an inside view of The Apothecary, visit https://vimeo.com/129493221.
In order to expand its retail distribution network and bypassing the costs of traditional brick and mortar locations, GrowBLOX Sciences will also offer a collection of Micro-Apothecary self-service vending kiosks, which will serve as phase two of the company’s retail channel solutions. These machines will provide validated patients with a quick and easy way to obtain the company’s products. Since the Micro-Apothecary can be installed in any existing retail location or traditional pharmacy permitted to sell medical cannabis products or distribute clinical trial medication doses. This prudent approach offers GBLX a cost-effective method of exponentially expanding its distribution network in the years to come.
The final phase of the company’s projected retail network is its innovative mobile app. Set to be released in the second half of 2015, this powerful tool will allow patients to generate profiles, track symptoms, browse local inventory options and order products for pickup or delivery through the use of a mobile device. This mobile app will be essential for tracking valuable patient data and streamline distribution efforts beyond the bounds of its physical locations in order to maximize potential growth moving forward.
With a full network of projected retail channel solutions in place, GBLX is in a solid position to promote strong returns in the future. In the coming months, look for the company to continue building upon its recent commercial progress in an effort to maximize market share within the expanding medicinal cannabis industry.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
